Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes
- The NICE recommends the use of finerenone (10 & 20mg) as a treatment option for CKD associated with T2D in adults
- The recommendation was based on the P-III study (FIDELIO-DKD) evaluating finerenone vs PBO in 5734 adult patients which showed a reduction in risk of the primary composite renal outcome of time to kidney failure, a decrease of eGFR ≥ 40% from baseline over 4wks. or death from renal causes by 18% (relative & absolute risk reduction 3.3%) over a median duration of follow-up of 2.6yrs., (17.8% vs 21.1%) experienced a primary composite renal outcome when added to an MTD of an ACE inhibitor or ARB
- 14% relative risk reduction in key secondary cardiovascular EPs, 13% vs 14.8% experienced a key secondary cardiovascular event over a median duration of 2.6yrs. follow-up
Ref: nice-publishes | Image: nice-publishes
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.